23 search results for: disease modification
ESPD 2024 | Atopic Dermatitis in Children: Can Early Therapeutic Intervention Shape Disease Course?
This symposium illustrated the ways type 2inflammation contributes to atopic dermatitis (AD) disease pathogenesis within and beyond the skin, discussed the importance of early intervention in children with AD, and explored the potential for disease modification. The program concluded with a review of the latest clinical and real-world data on advanced systemic treatments for children with AD.
Shifting Gears: Can Disease Course Be Changed in Patients With Pediatric Atopic dermatitis?
In this video from the 2024 Society for Pediatric Dermatology Symposium held in Toronto, Canada, Dr. Amy Paller, MD and Dr. Peter Lio, MD discusses the role of atopic dermatitis as a risk factor for developing food allergies. Moreover, explores the potential opportunities for early intervention to alter disease trajectories and the possibilities for disease modification in atopic dermatitis.
The Benefits of Early Intervention in AD: More Than Skin Deep
Many AD treatment goals focus on clinical manifestations, so that if a patient is free of lesions, their disease is considered well controlled. However, the inflammatory process underlying AD reaches far beyond the skin, affecting patients in unique ways at different stages of their lives. Education on the importance of treating AD beyond the skin and altering the treatment approach to fit the individual patient will help improve clinical management and reduce long-term patient burden.
Beyond the Skin: Cumulative Disease Burden in Children With Atopic Dermatitis
Dr. Lara Wine Lee discusses the concept of cumulative life course impairment in AD, focusing on non-atopic comorbidities like vertical growth deficits and mental health impairment and how these might be preventable with early intervention at PeDRA 2025.
The Growing Burden: Cumulative Disease Impact and Comorbidities in Pediatric AD
Dr. Yu and Dr. Wine Lee discuss the clinical presentation and burden of atopic dermatitis, the role of type 2 inflammation in the development of atopic comorbidities, and the importance of early intervention in potentially preventing cumulative life course impairment in AD at PeDRA 2025.
ADVENT at ERS 2025
Join leading pulmonologists across asthma and COPD for educational symposia at the ERS congress in Amsterdam, Netherlands.
Bullous Pemphigoid: Insights and Innovations
Experience this engaging presentation by Dr. Donna Culton, Prof. Dédée Murrell, and Prof. Ulrike Raap, who highlight the heterogeneous clinical presentations of BP and its burden, delve beneath the surface into how autoimmunity and predominantly type 2 inflammation mediate the disease, and explore the evolving toolbox of current approaches in BP management.
ADVENT On Air | Expert Discussions in Dermatology
Listen to the latest updates in type 2 inflammatory science and associated skin diseases, brought to you by leading dermatology experts in the field. ADVENT On Air podcasts feature scientific conversations that explore new research into the pathophysiology, clinical features, and disease burden for a range of dermatological diseases linked to type 2 inflammation, including atopic dermatitis (AD) and prurigo nodularis (PN). Hear new insights revealed through expert-led conversations below or in your preferred podcast app.
KOL Video Interview – Dr Paula Luna
In this exclusive video interview, Dr Paula Luna discusses how disease modification can be defined in AD and how IgE may be used as a biomarker in AD.
ERS 2025 Enduring Video: Type 2 Severe Asthma “Unplugged”: Reducing Mucus to Improve Long- Term Patient Outcomes
Join Drs. Njira Lugogo, Simon Couillard, and Mario Castro for a session exploring the link between pathogenic mucus and impaired lung function in patients with moderate-to-severe asthma and the potential for disease modification with targeted therapy.
ADVENT at WCPD 2025
The ADVENT symposium at the 15th World Congress of Pediatric Dermatology (WCPD) will focus on discussions around disease modification in atopic dermatitis (AD) in three main topic areas: restoring the skin barrier, reducing non-atopic comorbidities, and stopping the atopic march in pediatric patients with AD aged 6 months to 11 years.
